Clinical Trials Browser

NCT05564377 2026-04-16

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

89 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT05554328 2026-04-13

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase 2 Recruiting

165 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

554 enrolled

Gynecologic

Endometrial Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Gynecologic

Endometrial Neoplasms

NCT02755844 2025-10-02

ENDOLA

Phase 1/2 Completed

35 enrolled

Gynecologic

Endometrial Neoplasms

NCT05320757 2025-06-11

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Phase EARLY_PHASE1 Completed

20 enrolled

Gynecologic

Endometrial Neoplasms

NCT03745950 2024-12-04

UTOLA

Phase 2 Completed

147 enrolled

Gynecologic

Endometrial Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1 Terminated

24 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

30 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT03924245 2022-04-04

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1 Terminated

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03570437 2022-03-02

COPELIA

Phase 2 Unknown

124 enrolled

GynecologicSarcoma

Carcinosarcoma, Neoplasms, Endometrial Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

55 enrolled

Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT02506816 2020-11-30

Polen

Completed

36 enrolled 10 charts

Gynecologic

Endometrial Neoplasms

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase 1 Completed

77 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT02684318 2017-06-22

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

Phase 1/2 Unknown

100 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms